Serum anti-lysosomal-associated membrane protein-2 antibody levels in cutaneous polyarteritis nodosa

Acta Dermato-Venereologica

Volumn 93, Issue 1, 2013, Pages 70-73

  Kawakami, Tamihiro ^a   Ishizu, Akihiro ^b   Arimura, Yoshihiro ^c   Soma, Yoshinao ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti neutrophil cytoplasmic antibody; Cutaneous polyarteritis nodosa; Indirect immunofuorescence; Lysosomal associated membrane protein 2; Microscopic polyangiitis

Indexed keywords

ANTIBODY; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2 ANTIBODY; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; MALE; MICROSCOPIC POLYANGIITIS; PATHOGENESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; SKIN POLYARTERITIS NODOSA;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CASE-CONTROL STUDIES; COMPLEMENT C3; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; MYELOBLASTIN; PEROXIDASE; POLYARTERITIS NODOSA;

EID: 84871240570     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1418     Document Type: Article

References (20)

1. Kain R, Matsui K, Exner M, Binder S, Schaffner G, Sommer EM, et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glo-merulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995; 181: 585-597.
2. Tanaka Y, Guhde G, Suter A, Eskelinen EL, Hartmann D, Lullmann-Rauch R, et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-defcient mice. Nature 2000; 406: 902-906.
3. Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 2003; 13: 137-145.
4. Eskelinen EL, Schmidt CK, Neu S, Willenborg M, Fuertes G, Salvador N, et al. Disturbed cholesterol traffc but normal proteolytic function in LAMP-1/LAMP-2 double-defcient fbroblasts. Mol Biol Cell 2004; 15: 3132-3145.
5. Eskelinen EL, Illert AL, Tanaka Y, Schwarzmann G, Blanz J, von Figura K, et al. Role of LAMP-2 in lysosome biogenesis and autophagy. Mol Biol Cell 2002; 13: 3355-3368.
6. Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S. LAMP proteins are required for fusion of ly-sosomes with phagosomes. EMBO J 2007; 26: 313-324.
7. Salama AD, Pusey CD. Shining a LAMP on pauci-immune focal segmental glomerulonephritis. Kidney Int 2009; 76: 15-17.
8. Kain R, Exner M, Brandes R, ziebermayr R, Cunningham D, Alderson CA, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14: 1088-1096.
9. Willcocks LC, Lyons PA, Rees AJ, Smith KG. The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther 2010; 12: 202.
10. Roth AJ, Brown MC, Smith RN, Badhwar AK, Parente O, Chung HC, et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic au-toantibody glomerulonephritis. J Am Soc Nephrol 2012; 23: 545-555.
11. Moreland LW, Ball GV. Cutaneous polyarteritis nodosa. Am J Med 1991; 88: 426-430.
12. Nakamura T, Kanazawa N, Ikeda T, Yamamoto Y, Naka-bayashi K, Ozaki S, et al. Cutaneous polyarteritis nodosa: revisiting its defnition and diagnostic criteria. Arch Der-matol Res 2009; 301: 117-121.
13. Kawakami T. New algorithm (KAWAKAMI algorithm) to diagnose primary cutaneous vasculitis. J Dermatol 2010; 37: 113-124.
14. Kawakami T, Yamazaki M, Mizoguchi M, Soma Y. High titer of anti-phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa. Arthritis Rheum 2007; 57: 1507-1513.
15. Westman K, Selga D, Bygren P, Segelmark M, Baslund B, Wiik A, et al. Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody (PR3-ANCA). Kidney Int 1998; 53: 1230-1236.
16. Cornely OA, Hauschild S, Weise C, Csernok E, Gross WL, Salzberger B, et al. Seroprevalence and disease association of antineutrophil cytoplasmic autoantibodies and antigens in HIV infection. Infection 1999; 27: 92-96.
17. Savige JA, Chang L, Crowe SM. Anti-neutrophil cytoplasm antibodies in HIV infection. Adv Exp Med Biol 1993; 336: 349-352.
18. Lamprecht P, Gutzeit O, Csernok E, Gause A, Longom-bardo G, zignego AL, et al. Prevalence of ANCA in mixed cryoglobulinemia and chronic hepatitis C virus infection. Clin Exp Rheumatol 2003; 21: S89-94.
19. Schultz H, Csernok E, Herlyn K, Reichel PH, Moosig F, Cornely OA, et al. ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations. Clin Exp Rheumatol 2003; 21: S117-120.
20. Yahya TM, Benedict S, Shalabi A, Bayoumi R. Anti-neu-trophil cytoplasmic antibody (ANCA) in malaria is directed against cathepsin G. Clin Exp Immunol 1997; 110: 41-44.